• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immune checkpoint inhibitors in penile cancer.

作者信息

Buonerba Carlo, Scafuri Luca, Costabile Ferdinando, D'Ambrosio Bruno, Gatani Simona, Verolino Pasquale, Trolio Rossella Di, Cosimato Vincenzo, Verde Antonio, Lorenzo Giuseppe Di

机构信息

Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici 80055, Italy.

Oncology Unit, Hospital 'Andrea Tortora', ASL Salerno, Pagani, Italy.

出版信息

Future Sci OA. 2021 May 21;7(7):FSO714. doi: 10.2144/fsoa-2021-0044. eCollection 2021 Aug.

DOI:10.2144/fsoa-2021-0044
PMID:34258024
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8256326/
Abstract
摘要

相似文献

1
Immune checkpoint inhibitors in penile cancer.阴茎癌中的免疫检查点抑制剂。
Future Sci OA. 2021 May 21;7(7):FSO714. doi: 10.2144/fsoa-2021-0044. eCollection 2021 Aug.
2
Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.免疫检查点抑制剂在晚期阴茎癌中的安全性和疗效：来自全球罕见泌尿生殖系统肿瘤学会的报告。
J Natl Cancer Inst. 2023 Dec 6;115(12):1605-1615. doi: 10.1093/jnci/djad155.
3
Penile cancer: potential target for immunotherapy?阴茎癌：免疫治疗的潜在靶点？
World J Urol. 2021 May;39(5):1405-1411. doi: 10.1007/s00345-020-03510-7. Epub 2020 Nov 3.
4
Immune landscape and immunotherapy for penile cancer.阴茎癌的免疫景观与免疫疗法。
Front Immunol. 2022 Nov 29;13:1055235. doi: 10.3389/fimmu.2022.1055235. eCollection 2022.
5
Immune-based Therapies for Penile Cancer.基于免疫的阴茎癌治疗方法。
Urol Clin North Am. 2024 Aug;51(3):355-365. doi: 10.1016/j.ucl.2024.03.014. Epub 2024 Apr 16.
6
New Therapeutic Horizons for Advanced or Metastatic Penile Cancer.晚期或转移性阴茎癌的新治疗前景。
Urol Clin North Am. 2024 Aug;51(3):367-376. doi: 10.1016/j.ucl.2024.03.005. Epub 2024 May 18.
7
Therapeutic Approaches to Penile Cancer: Standards of Care and Recent Developments.阴茎癌的治疗方法：护理标准与最新进展
Res Rep Urol. 2023 Jun 2;15:165-174. doi: 10.2147/RRU.S387228. eCollection 2023.
8
Impact of the STK11/KRAS co-mutation on the response to immunotherapy in a real-world pan-cancer cohort.STK11/KRAS 共突变对真实世界泛癌队列免疫治疗反应的影响。
Tumori. 2024 Apr;110(2):146-152. doi: 10.1177/03008916231204441. Epub 2023 Oct 11.
9
Defining the Tumor Microenvironment of Penile Cancer by Means of the Cancer Immunogram.通过癌症免疫组图定义阴茎癌的肿瘤微环境。
Eur Urol Focus. 2019 Sep;5(5):718-721. doi: 10.1016/j.euf.2019.02.019. Epub 2019 Mar 9.
10
SPP1 is associated with adverse prognosis and predicts immunotherapy efficacy in penile cancer.SPP1 与不良预后相关，并可预测阴茎癌的免疫治疗疗效。
Hum Genomics. 2023 Dec 19;17(1):116. doi: 10.1186/s40246-023-00558-5.

引用本文的文献

1
Programmed death‑ligand 1 expression in tumor cells and tumor‑infiltrating lymphocytes are associated with depth of tumor invasion in penile cancer.肿瘤细胞和肿瘤浸润淋巴细胞中程序性死亡配体1的表达与阴茎癌肿瘤浸润深度相关。
Biomed Rep. 2023 May 29;19(1):44. doi: 10.3892/br.2023.1627. eCollection 2023 Jul.
2
Pembrolizumab as a promising intervention for advanced penile cancer.帕博利珠单抗作为晚期阴茎癌的一种有前景的干预措施。
Int Braz J Urol. 2022 Jul-Aug;48(4):719-721. doi: 10.1590/S1677-5538.IBJU.2022.99.17.

本文引用的文献

1
Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial.帕博利珠单抗治疗晚期阴茎癌：来自 II 期篮子试验的病例系列。
Invest New Drugs. 2021 Oct;39(5):1405-1410. doi: 10.1007/s10637-021-01100-x. Epub 2021 Mar 26.
2
Case Report: Two Cases of Chemotherapy Refractory Metastatic Penile Squamous Cell Carcinoma With Extreme Durable Response to Pembrolizumab.病例报告：两例化疗难治性转移性阴茎鳞状细胞癌对帕博利珠单抗产生极其持久反应
Front Oncol. 2020 Dec 23;10:615298. doi: 10.3389/fonc.2020.615298. eCollection 2020.
3
Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies.多中心、2 期研究纳武利尤单抗和伊匹单抗治疗晚期罕见泌尿生殖系统恶性肿瘤患者的结果。
Cancer. 2021 Mar 15;127(6):840-849. doi: 10.1002/cncr.33328. Epub 2020 Nov 20.
4
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.帕博利珠单抗或帕博利珠单抗联合化疗对比单纯化疗用于一线晚期胃癌患者的疗效和安全性：KEYNOTE-062 期随机临床研究。
JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi: 10.1001/jamaoncol.2020.3370.
5
The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.PD-1/PD-L1 抑制剂联合常规疗法治疗晚期实体瘤的疗效和安全性：一项荟萃分析。
Biomed Res Int. 2020 May 6;2020:5059079. doi: 10.1155/2020/5059079. eCollection 2020.
6
Metastatic penile squamous cell carcinoma with dramatic response to combined checkpoint blockade with ipilimumab and nivolumab.转移性阴茎鳞状细胞癌对伊匹单抗和纳武利尤单抗联合检查点阻断治疗有显著反应。
J Oncol Pharm Pract. 2021 Jan;27(1):212-215. doi: 10.1177/1078155220922602. Epub 2020 May 7.
7
PD-L1 and p16 Expression in Penile Squamous Cell Carcinoma From an Endemic Region.PD-L1 和 p16 在地方性流行区阴茎鳞癌中的表达。
Clin Genitourin Cancer. 2020 Jun;18(3):e254-e259. doi: 10.1016/j.clgc.2019.10.014. Epub 2019 Oct 16.
8
Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis.抗 PD-1/PD-L1 抑制剂治疗晚期或转移性癌症的临床疗效和安全性：系统评价和荟萃分析。
Sci Rep. 2020 Feb 7;10(1):2083. doi: 10.1038/s41598-020-58674-4.
9
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
10
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.西妥昔单抗联合 PD-1 抑制剂治疗晚期皮肤鳞状细胞癌的疗效和安全性
N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4.